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Abstract 
Immunological hallmarks of multiple sclerosis include the production of antibodies in the 
central nervous system, expressed as presence of oligoclonal bands and/or an increased 
Immunoglobulin G index, the level of immunoglobulin G in the cerebrospinal fluid compared 
to serum. However, the underlying differences between oligoclonal band positive and 
negative MS patients and reasons for variability in Immunoglobulin G index are not known. 
In order to identify genetic factors influencing the variation in the antibody levels in the 
cerebrospinal fluid in multiple sclerosis, we have performed a genome-wide association 
screen in patients collected from nine countries for two traits, presence or absence of 
oligoclonal bands (n=3,026) and Immunoglobulin G index levels (n=938), followed by a 
replication in 3,891 additional patients. We replicate previously suggested association signals 
for oligoclonal band status in the Major Histocompatibility Complex region for the 
rs9271640*A-rs6457617*G haplotype, correlated with HLA-DRB1*1501, and 
rs34083746*G, correlated with HLA-DQA1*0301 (P comparing two haplotypes = 8.88E-16). 
Furthermore, we identify a novel association signal of rs9807334, near the ELAC1/SMAD4 
genes, for oligoclonal band status (P = 8.45E-07). The previously reported association of the 
Immunoglobulin Heavy Chain locus with Immunoglobulin G index reaches strong evidence 
for association in this dataset (P = 3.79E-37). We identify two novel associations in the Major 
Histocompatibility Complex region with Immunoglobulin G index: the rs9271640*A-
rs6457617*G haplotype (P = 1.59E-22), shared with oligoclonal band status, and an 
additional independent effect of rs6457617*G (P = 3.68E-06). Variants identified in this 
study account for up to two-fold differences in the odds of being oligoclonal band positive 
and 7.75 % of the variation in Immunoglobulin G index. Both traits are associated with 
clinical features of disease such as female gender, age at onset and severity. This is the largest 
study population so far investigated for the genetic influence on antibody levels in the 
cerebrospinal fluid in multiple sclerosis, including 6,950 patients. We confirm that genetic 
factors underlie these antibody levels and identify both the Major Histocompatibility Complex 
and Immunoglobulin Heavy Chain region as major determinants. 
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Abbreviations: 
AAO Age at onset 
HLA Human Leukocyte Antigen 
IgG Immunoglobulin G 
MHC Major Histocompatibility Complex 
MSSS Multiple Sclerosis Severity Score 
OCB oligoclonal band 
OR Odds Ratio 
PP Primary Progressive 
SNP Single Nucleotide Polymorphism 
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Introduction 
Multiple sclerosis is a neurological disease characterized by inflammation, demyelination and 
axonal degeneration, and is an important cause of disability in young adults (Compston and 
Coles, 2008). The etiology is not known, but both genetic and environmental factors influence 
disease susceptibility (Compston and Coles, 2008). An association between multiple sclerosis 
and the Human Leukocyte Antigen (HLA) genes in the Major Histocompatibility Complex 
(MHC) region has been identified early on (Jersild et al., 1972), and has later been refined to 
four independent association signals of which HLA-DRB1*15:01 is the strongest (The 
International Multiple Sclerosis Genetics Consortium and The Wellcome Trust Case Control 
Consortium 2, 2011). Recently, knowledge of non-HLA associations in multiple sclerosis has 
increased extensively and immunologically relevant genes are overrepresented amongst those 
mapping close to the identified risk variants (The International Multiple Sclerosis Genetics 
Consortium and The Wellcome Trust Case Control Consortium 2, 2011, The International 
Multiple Sclerosis Genetics Consortium, 2013).  
An immunological hallmark in multiple sclerosis is the finding of oligoclonal bands (OCBs) 
and/or increased Immunoglobulin G (IgG) index in the cerebrospinal fluid (Stangel et al., 
2013). OCBs are reported to be observed in 90-95 % of patients in Northern Europe, and are 
composed predominantly of IgG. The IgG index contrasts the cerebrospinal fluid/serum IgG 
ratio to the cerebrospinal fluid/serum albumin ratio (Link and Huang, 2006). There are strong 
indications that antibody levels in the cerebrospinal fluid are influenced by genetic factors, 
since cerebrospinal fluid abnormalities are seen in 19% of unaffected siblings of multiple 
sclerosis patients as opposed to 4% of healthy unrelated individuals (Haghighi et al., 2000). 
Also, the OCB positive rates, as well as the IgG index are reported to correlate with ethnicity 
(Fukazawa et al., 1998, Kikuchi et al., 2003, Rinker et al., 2007, Lechner-Scott et al., 2011, 
Yoshimura et al., 2014), although not observed in all studies (Berg-Hansen et al., 2013). 
The role of the HLA loci in determining OCB status has been highlighted previously 
(Fukazawa et al., 1998, Kikuchi et al., 2003, Imrell et al., 2006, Idiman et al., 2009, Wu et 
al., 2009, Romero-Pinel et al., 2011, Leone et al., 2013, Mero et al., 2013, Yoshimura et al., 
2014). Most recently, large study populations from Scandinavia and Italy have shown HLA-
DRB1*15∶01 to be associated with OCB positive and HLA-DRB1*04∶04 with OCB negative 
multiple sclerosis, respectively (Leone et al., 2013, Mero et al., 2013). Furthermore, the 
immunoglobulin heavy chain (IGHC) region was recently reported to be highly correlated 
with IgG index in German and Belgian multiple sclerosis patients (Buck et al., 2012).  
In the present study we aim to further determine the genetic impact on IgG levels in the 
cerebrospinal fluid in multiple sclerosis. We combine genome-wide single nucleotide 
polymorphism (SNP) data (The International Multiple Sclerosis Genetics Consortium and The 
Wellcome Trust Case Control Consortium 2, 2011) with available cerebrospinal fluid data in 
a meta-analysis of 3,059 multiple sclerosis patients and replicate top-hits from the screening 
phase in 3,891 additional samples. The combined dataset of 6,950 patients from nine 
countries is the largest study population so far to investigate both clinical and genetic factors 
associated with OCB status and IgG index and we replicate three previously described 
associations and identify three new genetic differences underlying cerebrospinal fluid 
phenotypes. 
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Methods 
Study populations  
The 3,059 multiple sclerosis samples included in the screening phase of this study are a subset 
of the samples that were previously used in a genome-wide association study  on multiple 
sclerosis susceptibility (The International Multiple Sclerosis Genetics Consortium and The 
Wellcome Trust Case Control Consortium 2, 2011). Eight countries provided OCB status 
(positive or negative) for 3,026 patients in the screening phase, while five countries provided 
IgG index for 938 patients (Table 1). In the replication phase, 3,891 additional multiple 
sclerosis samples (3,842 with OCB status and 2,188 with IgG index) were provided by eight 
countries. The combined screening and replication cohort included OCB status on 6,868 
patients and IgG index on 3,126 patients from the following countries: Australia, Belgium, 
Denmark, Germany, Italy, Norway, Spain, Sweden and USA (Table 1). For a total of 3,044 
patients, both OCB status and IgG index were available. For the genetic analyses, 3,478 
patients with OCB status and 2,072 patients with IgG index survived genetic quality control in 
the replication phase (see further), leading to a final sample size of 6,504 for OCB status and 
3,010 for IgG index in the combined genetic analyses. 
 
Cerebrospinal fluid analyses 
All patients included in this study fulfilled Poser or McDonald multiple sclerosis criteria 
(Poser et al., 1983, McDonald et al., 2001) or were diagnosed as clinically isolated syndrome 
(n = 7 (0.2%) in screening phase (Germany); n = 138 (3.5%) in replication phase (Germany)), 
based on the combination of (1) a clinical symptom being typical and suggestive for multiple 
sclerosis, (2) a magnetic resonance imaging of the brain and in most cases also of the spinal 
cord demonstrating typical multiple sclerosis lesions fulfilling the criteria of dissemination in 
space (Barkhof criteria or Swanton criteria) and (3) cerebrospinal fluid parameters. In most 
countries recruiting samples to this study, lumbar puncture is done routinely as part of the 
diagnostic process and is seldom repeated unless the diagnosis is unclear. OCB status is 
considered positive when more than one OCB was seen in the cerebrospinal fluid that was not 
present in the serum. IgG index is considered positive for values >0.7. In this study the IgG 
index value was used in quantitative trait statistical analyses after transforming the IgG index 
ratio by taking the logarithm (base 2) (log2 IgG).  
 
Clinical analyses 
The clinical parameters gender, age at onset (AAO), multiple sclerosis severity score (MSSS) 
(Roxburgh et al., 2005), disease course and disease duration at lumbar puncture were included 
in the clinical analyses. Statistical analyses of cerebrospinal fluid phenotypes related to 
demographic and clinical parameters were done in R 2.14.1 (www.r-project.org) using linear 
regression for IgG index and logistic regression for the binary OCB status. We included 
covariates in the analyses as indicated. 
 
Screening phase 
Quality control and analysis of genetic data provided in the multiple sclerosis genome-wide 
association study (The International Multiple Sclerosis Genetics Consortium and The 
Wellcome Trust Case Control Consortium 2, 2011) were performed with Plink v1.07 (Purcell 
et al., 2007).  For OCB status, we used a qualitative trait analysis in a logistic regression with 
binary outcome (OCB pos/neg). For IgG index, we applied a quantitative trait analysis in a 
linear regression with allele dosage as independent variable and IgG index as dependent 
outcome. In the screening phase, gender and the seven main principal components previously 
determined in this dataset (The International Multiple Sclerosis Genetics Consortium and The 
Wellcome Trust Case Control Consortium 2, 2011) were associated with IgG index and hence 
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added as covariates for IgG index analyses. Evidence of association was tested in samples 
from each country individually and combined in a fixed-effects meta-analysis (assuming a 
qualitative trait for OCB and quantitative trait for IgG) over all countries. P-values < 5E-08 
and < E-4.5 in the screening phase were considered as genome-wide significant and 
suggestive evidence, respectively, as applied previously (The International Multiple Sclerosis 
Genetics Consortium and The Wellcome Trust Case Control Consortium 2, 2011). For each 
lead SNP a conditional analysis of the surrounding 3 Mb region was performed, and SNPs 
reaching P < E-04 were considered suggestive in this analysis.  
Power for OCB analysis was determined mainly by the typical frequency of OCB negative 
status in a multiple sclerosis study population. In the screening phase, we had 80% power to 
detect suggestive evidence (P < E-4.5) for variants with a minor allele frequency of 0.20 and 
an odds ratio of 1.6. Power was 80% for variants explaining 2.5% of the variation in the 
distribution of IgG index seen in multiple sclerosis patients. 
 
Replication phase  
In total, 42 SNPs were selected for replication. Of these, 38 SNPs were brought forward to 
replication based on the results from the screening phase; 32 lead SNPs reaching P < E-4.5, 
an additional proxy marker for rs6457617 (rs9275224 with r
2 
= 1), and five SNPs with 
conditional association signals of P < E-04. Additionally, we added two SNPs that were 
previously suggested to be associated with OCB status (Leone et al., 2013, Mero et al., 2013) 
and two SNPs reported to be associated to autoantibody presence in other tissues (Ferreira et 
al., 2010, Plagnol et al., 2011) and showing association or a trend for association with IgG 
index in our study. The SNPs were genotyped using Sequenom MassArray iPLEX technology 
(Sequenom Inc, San Diego, CA). Sequenom MassArray Designer software v3.1 was used to 
design primers and extension probes. As part of validating the design, a test set of genotyping 
data from 86 individuals generated with Illumina platforms was included. Seven SNPs were 
replaced by proxies with moderate to high linkage disequilibrium (r
2 
> 0.63). For two SNPs, 
no assay could be designed and for two others genotyping assays failed, therefore a total of 38 
SNPs were successfully included in the replication analysis (i.e. 28 lead SNPs and one 
synonym, five conditional SNPs and four SNPs selected from previous studies) 
(Supplementary Material). 75 ng of genomic DNA was used in five μl reactions in 384-well 
plates. The amplified resin-treated DNA was spotted with a Sequenom MassArray 
Nanodispenser (Sequenom Inc, San Diego, CA) on a SpectroCHIP Array. The SpectroCHIP 
Arrays were analyzed using a Sequenom MALDI-TOF mass spectrometry (Sequenom Inc, 
San Diego, CA). Genotyping calls were automatically generated using the MassARRAY 
TyperAnalyzer software v4.0 (Sequenom Inc, San Diego, CA) and were validated by manual 
review of the raw mass spectra scatter plots. 
Genotyping quality control was performed in samples grouped per country. Samples with > 
4/38 missing genotypes (< 89.5% sample success rate) and SNPs with < 95% genotyping 
success rate were excluded from further analysis. No SNPs deviated from Hardy-Weinberg 
equilibrium (P < 1E-04), except for a known multiple sclerosis susceptibility SNP in the 
MHC region in the Norwegian population. Analysis was performed per country with a linear 
model including gender as covariate for IgG and a logistic model for OCB, followed by a 
fixed-effects meta-analysis over all countries. An effect was considered replicated when 
reaching P < 0.05 in the replication phase. 
 
Combined analyses 
Analysis was performed by a fixed-effects meta-analysis over all cohorts (screening and 
replication cohorts per country as described before). The percentage of the variance in IgG 
index explained by variants was calculated by subtracting adjusted r
2
 from a full model with 
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that from the baseline linear model in R. Evidence for interaction between variants, defined as 
deviation from a multiplicative model, was investigated in a linear (IgG index) or logistic 
(OCB status) regression in R.  
 
MHC analyses 
In the screening phase HLA-A, -B, -C, -DRB1, -DQA1 and -DQB1 genotypes were imputed 
from SNP data as described previously (Dilthey et al., 2011, The International Multiple 
Sclerosis Genetics Consortium and The Wellcome Trust Case Control Consortium 2, 2011). 
The most likely imputed alleles were used as input for testing of association of common HLA 
alleles with cerebrospinal fluid phenotypes using the same regression approach as described 
for SNPs above. Independent effects of SNPs/haplotypes in the MHC region were 
investigated with a likelihood ratio test for OCB status or F test for  IgG index comparing a 
null model and alternative model for phased haplotypes with a minor haplotype frequency of 
0.05 including country, seven principal components (screening phase only) and gender as 
covariates (--chap option in Plink v1.07). The most likely model was obtained by starting with 
a null model with equal effects for all haplotypes consisting of known and novel replicated 
MHC signals and allowing separate effects for individual haplotypes, in order of significance, 
as long as this improved the model with nominal significance. 
 
 
Multiple Sclerosis Genetic Burden 
In the screening phase, a genetic risk score, Multiple Sclerosis Genetic Burden, was 
calculated on the basis of the number of risk alleles weighted by their effect on multiple 
sclerosis risk according to the method described previously (Gourraud et al., 2011, Harbo et 
al., 2014). Two scores were calculated, both including the 57 risk SNPs and either including 
or excluding alleles imputed as above for the four HLA effects (HLA-DRB1*15:01, 
DRB1*03:01, DRB1*13:03 and HLA-A*02:01) established in our previous genome-wide 
association study on susceptibility including this dataset (The International Multiple Sclerosis 
Genetics Consortium and The Wellcome Trust Case Control Consortium 2, 2011). A logistic 
regression analysis with country as covariate was performed for OCB status, whereas a linear 
regression analysis including country, gender and seven principal components was performed 
for IgG index in R. 
 
Results 
Clinical and cerebrospinal fluid analyses 
The main demographic and clinical characteristics of patients included in the screening and 
replication phase, stratified by country of origin, are described in Table 1. Among 6,868 
multiple sclerosis patients with known OCB status, 6,033 (88%) were OCB positive. The IgG 
index level in patients recruited from different countries is shown in Supplementary Fig. 1. 
An elevated IgG index was found in 1,996 of 3,126 patients with known IgG index (64%). 
IgG index was on average lower in Italian and higher in Danish and Norwegian patients. For a 
total of 3,044 patients, both OCB status and IgG index were available. Increased IgG index 
was highly correlated with OCB status (P < 2E-16) in the combined dataset (Table 2,  
Supplementary Fig. 2). Overall, 62% of the multiple sclerosis patients were positive and 10% 
were negative for both OCB and IgG index (Supplementary Table 1). On average, 26% of the 
patients were OCB positive but did not have an increased IgG index. An increased IgG index 
in OCB negative multiple sclerosis patients was very rare (2%).  
Gender was highly correlated with both IgG index and OCB status. Women had on average a 
1.12-fold higher IgG index (P = 1.9E-10) and were 1.3-fold more likely to be OCB positive 
than men (P = 9.7E-04) (Table 2, Supplementary Fig. 3). There was no correlation either 
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between IgG index or OCB status and the interval between diagnosis and lumbar puncture 
(median of 1 year). Younger patients had higher IgG indices (P = 0.0028), and were more 
likely to be OCB positive (P = 0.013). We found no correlation between multiple sclerosis 
subtype (bout onset or progressive onset) and IgG index or OCB status after correction for 
gender and AAO. Patients with a higher IgG index were more severely affected, as assessed 
by the MSSS (P = 4.0E-04). 
 
Genome-wide association screen 
After quality control of the screening data, a total of 485,522 SNPs in 3,026 samples and 
485,236 SNPs in 938 samples were available for the analysis of OCB status and IgG index, 
respectively (Supplementary Table 2). Genomic inflation factor was 0.987 for OCB and 1.015 
for IgG index (Supplementary Fig. 4). 
We first performed a genome-wide analysis of all SNPs and cerebrospinal fluid data available 
(Fig. 1). Markers in the MHC region on chromosome 6 were associated with OCB status with 
genome-wide significance (P < 5E-08). We identified two regions showing genome-wide 
significance for association based on the IgG index, the MHC region on chromosome 6 and 
the IGHC region on chromosome 14. In addition, 14 lead SNPs and two conditional SNPs, 
and 15 lead SNPs and three conditional SNPs reached suggestive evidence for OCB status 
and IgG index, respectively (Tables 3 and 4), and were thus taken forward to replication.  
When analyzing the 57 multiple sclerosis risk SNPs previously identified in the genome-wide 
association study (The International Multiple Sclerosis Genetics Consortium and The 
Wellcome Trust Case Control Consortium 2, 2011) (Supplementary Table 3), one SNP 
(rs12368653) showed nominally significant association with OCB positivity. For IgG index, 
seven of these 57 SNPs (12%) reached nominal significance. The multiple sclerosis associated 
risk allele increased the IgG index for five of these SNPs. Since the contribution to the overall 
multiple sclerosis risk of each of these SNPs is small, we also estimated the Multiple Sclerosis 
Genetic Burden. This genetic risk score was composed of 57 established non-HLA multiple 
sclerosis risk SNPs and four classical HLA alleles (Gourraud et al., 2011, The International 
Multiple Sclerosis Genetics Consortium and The Wellcome Trust Case Control Consortium 2, 
2011). A higher Multiple Sclerosis Genetic Burden including the HLA alleles was associated 
with increased IgG index [fold change = 1.11 (95% CI: 1.07-1.15), P = 1.33E-09] and OCB 
status [OR = 1.51 (95% CI: 1.32-1.74), P = 3.44E-09], whereas these associations were 
substantially reduced when considering only non-HLA risk SNPs [IgG index: fold change = 
1.06 (95% CI: 1.00-1.13), P = 0.038; OCB: OR = 1.19 (95% CI: 0.96-1.48), P = 0.12], 
indicating the MHC region as the main contributor. 
Subsequently, we investigated SNPs known from the literature to be associated with the 
presence of antibodies in diverse other tissues (Pubmed and Catalogue of Genome-wide 
Association Studies 4/12/2012) (Supplementary Table 4). A SNP tagging HLA-DRB1*15:01 
(rs3129934), which is reported to be protective against IgA deficiency, increased IgG index (P 
= 1.37E-07) as well as the risk of OCB positivity in multiple sclerosis (P = 3.7E-04). 
 
Replication 
A total of 42 SNPs were taken forward to the replication phase and 38 SNPs were 
successfully genotyped (Supplementary Table 5). After quality control (Supplementary Table 
6), a total of 3,478 patients with OCB status and 2,072 with IgG index data available were 
analyzed. The same two regions that were associated with genome-wide significance with IgG 
index in the screening phase, i.e. the MHC and IGHC region, reached genome-wide 
significance in the replication phase as well (Tables 3 and 4). One novel non-MHC region 
(rs9807334 near ELAC1 - SMAD4) was replicated with nominal significance for association 
with OCB status.  
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Combined analyses 
Given the highly significant correlation between OCB status and IgG index, we compared 
results from a detailed analysis of the MHC class II region for both characteristics 
(Supplementary Table 7 and Fig. 2). The most likely model in the combined analysis included 
two independent effects in the MHC class II region on OCB status; a major effect of the 
rs9271640*A-rs6457617*G haplotype and an additional effect of rs3957148 (tagging SNP 
with r
2 
= 0.63 for rs34083746 identified in the screening phase). The first signal is highly 
correlated with the HLA-DRB1*1501 haplotype (r
2 
= 0.94), whereas the second is strongly 
correlated with HLA-DQA1*0301 (rs34083746: r
2 
= 0.93, rs3957148: r
2 
= 0.64), and more 
modestly with both HLA-DRB1*0401 (rs34083746: r
2 
= 0.39) and *0404 (rs34083746: r
2 
= 
0.26). Carrying the MHC SNP allele associated with OCB positive status at these loci, was 
associated with a two-fold higher likelihood of being OCB positive than carrying the allele 
associated with OCB negative status at all three loci [OR = 2.25 (95% CI 1.84-2.75), P = 
8.88E-16) (Fig. 2A). The rs9271640*A-rs6457617*G haplotype, correlated with DRB1*1501, 
was associated not only with OCB status, but also IgG index (P = 1.59E-22) (Fig. 2B). 
Independent of this haplotype, rs6457617*G had an additional effect increasing IgG index (P 
= 3.68E-06). Notably, the association of rs6457617 with IgG index was observed in both 
OCB positive (P = 4.22E-10) and OCB negative multiple sclerosis patients (P = 6.12E-04). 
SNP rs6457617 is only modestly associated with any classical HLA allele (r
2 
< 0.30). SNP 
rs34083746/rs3957148, correlated with DQA1*0301 and associated with OCB negative 
status, did not appear to influence IgG index levels. No interaction amongst the associated 
SNPs in the MHC region or between these and the SNP in the IGHC region was observed 
(data not shown). 
The previously reported association of IgG index with SNPs in the IGHC region was 
replicated as highly significant in the combined dataset (P = 3.79E-37) and explains 4.7 % of 
the variance in IgG index in the entire dataset. The MHC and IGHC region, the major 
determinants of variation in IgG index, together explain 7.75% of variance and combined with 
gender and country, account for 12.65% of variance in IgG index throughout Europe. Forest 
plots for all association signals per country are given in Supplementary Fig. 5 and 6. 
We also investigated the correlation between the main four established genetic effects and 
AAO, disease course and MSSS with covariates gender and, for the latter two, AAO. After 
correcting for multiple testing, the A-allele of rs9271640 (that was associated with increased 
IgG levels and likelihood of OCB positive status), was associated with lower AAO (Pscreen = 
4.44E-04, Preplication = 0.082, Pcombined = 5.68E-04). In contrast, at the IGHC locus, the allele 
that increased IgG index showed association with a later AAO (Pscreen = 0.011, Preplication = 
0.0066, Pcombined = 8.23E-05) (Supplementary Fig. 7).  
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Discussion 
This study is the largest to date that investigates genetic differences, clinical and 
demographical characteristics in relation to OCB status (N=6,868) and IgG index (N=3,126) 
in multiple sclerosis. Our findings strongly support that multiple sclerosis patients with and 
without OCBs and/or increased IgG index are genetically distinct. This has previously been 
suggested in other, smaller studies (Kikuchi et al., 2003, Imrell et al., 2006, Idiman et al., 
2009, Wu et al., 2009, Romero-Pinel et al., 2011, Buck et al., 2012, Leone et al., 2013, Mero 
et al., 2013, Yoshimura et al., 2014) and is now confirmed. In accordance with our previous 
observations and those of others (Lechner-Scott et al., 2011, Mero et al., 2013, Stangel et al., 
2013), multiple sclerosis patients with high cerebrospinal fluid antibody levels, as 
characterized by OCB positive status and/or high IgG index, more often are women and seem 
to have a lower AAO and higher MSSS. We find that the two cerebrospinal fluid parameters 
included in this study, OCB status and IgG index, are highly correlated (Mayringer et al., 
2005, Link and Huang, 2006, Rinker et al., 2007), supporting that these measurements reflect 
the same immunological process. 
Recently, the IGHC locus on chromosome 14 was reported to be associated with IgG index in 
Belgian and German multiple sclerosis patients (Buck et al., 2012). This is convincingly 
replicated in the present extended study with the finding of a strong association of rs11621145 
to IgG index (Pcombined = 3.79E-37). In addition, we identify two novel association signals in 
the MHC region as major genetic determinants for IgG index; rs9271640 which is correlated 
with the HLA-DRB1*15:01 allele, and rs6457617 which is located near the HLA-DQA1 gene 
but not known to tag any conventional HLA-allele. An interaction between HLA and IGHC 
has been suggested (Pandey, 2013); however we do not find any evidence to support this 
hypothesis. Together, these three SNPs from the MHC and IGHC regions explain 
approximately 7.75 % of the variance in IgG index.  
Several studies have suggested that OCB positive and OCB negative multiple sclerosis 
patients are associated with different HLA-DRB1 alleles (Kikuchi et al., 2003, Imrell et al., 
2006, Idiman et al., 2009, Wu et al., 2009, Romero-Pinel et al., 2011, Leone et al., 2013, 
Mero et al., 2013, Yoshimura et al., 2014). We observe a significant association of SNP 
rs9271640 tagging HLA-DRB1*15:01 with OCB status and a high correlation of the Multiple 
Sclerosis Genetic Burden including HLA risk alleles with OCB status. Our findings hence 
support previous observations of the major established multiple sclerosis risk allele, HLA-
DRB1*15:01, being more strongly associated with OCB positive multiple sclerosis than OCB 
negative multiple sclerosis. The present study also detects a significant difference between 
OCB positive and negative patients with regard to rs34083746. This SNP is highly correlated 
with the DQA1*0301 allele shared between DRB1*04 haplotypes. Hence, our findings are 
consistent with several HLA-DRB1*04 alleles having been shown to increase risk for OCB 
negative multiple sclerosis, but not OCB positive multiple sclerosis, in previous studies from 
Europe and Japan (Kikuchi et al., 2003, Imrell et al., 2006, Mero et al., 2013, Yoshimura et 
al., 2014). The combination of variation in the MHC region has a major impact on the OCB 
status of multiple sclerosis patients, resulting in a more than two-fold difference in the odds of 
being OCB positive. In addition to replicating previously suggested associations to OCB 
status within the MHC region, our analyses provide evidence for a novel locus to be 
associated with OCB status, rs9807334 near the ELAC1/SMAD4 genes. The SMAD4 gene, a 
signal transduction protein in the tumor growth factor beta pathway, has previously been 
implicated in class switch recombination and in Experimental Autoimmune 
Encephalomyelitis and multiple sclerosis (Park et al., 2005, Meoli et al., 2010, Huss et al., 
2011) and the same allele has previously been suggested as associated with vaccine response 
(Ovsyannikova et al., 2012).  
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The cerebrospinal fluid phenotype association signals in the MHC region we observe have 
been associated with susceptibility and antibody levels in other diseases. The HLA-
DRB1*1501-DQB1*0601 haplotype has been associated with either the presence or increased 
quantity of immunoglobulins of the IgG, IgA and IgM families both in healthy controls and in 
disease, including total immunoglobulins (Ferreira et al., 2010), antibodies induced by viruses 
such as Epstein-Barr virus (Rubicz et al., 2013), and autoantibodies in type 1 diabetes (Ishii et 
al., 2005) and Sjögren syndrome (Gottenberg et al., 2003) though an opposite correlation is 
seen for few other antibody responses (Sundqvist et al., 2014). HLA-DQA1*0301, highly 
correlated with  SNP rs34083746, is associated with autoantibody negative disease in ketosis-
prone diabetes (Oak et al., 2014). SNP rs6457617 is a major susceptibility factor in 
rheumatoid arthritis and systemic sclerosis, independent of classical HLA alleles (The 
International MHC and Autoimmunity Genetics Network, 2009, Radstake et al., 2010, 
Allanore et al., 2011, Orozco et al., 2014). Of note, the risk allele for these autoimmune 
diseases decreases the IgG levels in multiple sclerosis. The IGHC locus, on the other hand, 
has not been associated with antibody levels in other diseases as yet. Overall, the MHC region 
may enhance antibody production and OCB positive status, whereas the IGHC region has 
been proposed to influence clearance of antibodies from the cerebrospinal fluid and hence 
immunoglobulin levels (Buck et al., 2012). 
Other studies have shown that IgG levels correlate with the number of B cells, more 
particularly the number of plasmablasts, in the cerebrospinal fluid (Rudick et al., 1999, Cepok 
et al., 2001, Cepok et al., 2005). B cell follicles in the meninges have been found in a subset 
of multiple sclerosis patients and are suggested to play a pathogenic role (Magliozzi et al., 
2007). Moreover, a prognostic potential of findings in the cerebrospinal fluid has been 
proposed, since positivity for OCB is reported to double the risk of developing clinically 
definite multiple sclerosis in clinically isolated syndrome patients (Tintore et al., 2008). Also, 
some studies suggest that the inflammation in the brain reflected by cerebrospinal fluid 
alterations may correlate with neurodegeneration and disease progression (Stangel et al., 
2013). Our findings of a lower AAO and a higher MSSS in the multiple sclerosis patients 
with marked cerebrospinal fluid antibody levels support this hypothesis. In our study, HLA-
DRB1*15:01 increases cerebrospinal fluid antibody levels and lowers AAO, as reported 
previously (Hensiek et al., 2002, The International Multiple Sclerosis Genetics Consortium 
and The Wellcome Trust Case Control Consortium 2, 2011). However, at the IGHC locus, the 
allele increasing IgG index appears correlated with higher AAO, indicating that the 
mechanisms underlying the correlation between genetic determinants, cerebrospinal fluid 
antibody levels and clinical outcome are not fully understood as yet. 
The present study is well-powered, and the clinical characteristics of the patients included 
support that they are representative for multiple sclerosis patients in general. On average, 
OCB positivity was found in 88 % and an elevated IgG index in 64 % of patients, in 
accordance with earlier studies (Dobson et al., 2013, Stangel et al., 2013). Lumbar puncture is 
routinely performed as a part of the diagnostic process in most of the countries included, but a 
possible selection bias must be kept in mind when interpreting the clinical findings. OCBs 
and/or increased IgG index in the cerebrospinal fluid are clinically important hallmarks in 
multiple sclerosis, and in this large study we show that these disease phenotypes are 
associated with both genetic variants and clinical and demographic characteristics. The 
presence of intrathecal immunoglobulin M has been reported as an additional cerebrospinal 
fluid characteristic in multiple sclerosis patients that may be associated with unfavourable 
outcome or aggressive disease (Stangel et al., 2013). The study of genetic factors underlying 
immunoglobulin M levels is currently hampered by the availability of data but will be of 
future interest.   
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In summary, in this large study including 6,950 multiple sclerosis patients, we confirm that 
genetic variants in the immunologically important regions of MHC and IGHC influence OCB 
status and IgG index in multiple sclerosis patients.  
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Figure Legends 
Fig. 1. Manhattan plot of genome-wide association screen for A. OCB status and B. IgG 
index. 
Red line indicates genome-wide significance, blue line suggestive evidence. 
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Fig. 2. Most likely model for MHC class II haplotypes (composed of SNPs rs9271640-
rs6457617-rs3957148) and cerebrospinal fluid phenotype in the combined analysis: A. 
OCB status and B. IgG index. GAG haplotype is correlated with HLA-DQA1*0301 (r
2 
= 
0.64), AGA haplotype with HLA-DRB1*1501 (r
2 
= 0.94). P values are given compared to 
reference haplotypes. 
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